Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Managing Multiple Rheumatic Diseases: How One Patient Copes with Her Disabilities & Advocates for Others

Karen Appold  |  November 28, 2018

As a means to vent her frustration about her life with chronic illnesses, in 2012, Ms. Conway started the blog “As My Joints Turn: My Autoimmune Soap Opera.”

“Initially, it was a way to get my thoughts and feelings out,” she says. “Eventually, other patients started to find it, and suddenly, I had a following. It’s comforting to write about a difficult day and have a bunch of fellow patients understand me. It’s a big comfort to know I’m not alone.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ms. Conway also joined autoimmune and arthritis groups on Facebook to find like-minded people facing similar challenges. “They give good advice or just listen when I need to vent,” she says. “Some of my online friends understand me the best.”

Advocacy
Throughout her career as a speech-language pathologist, Ms. Conway has advocated for her clients’ rights to education and accessibility. She has attended rallies for education rights, contacted state government representatives regularly and participated in awareness campaigns for autism. At one point a colleague remarked, “Wouldn’t it be great if someone advocated for you the way you do for your students?”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This was a light bulb moment for Ms. Conway. It began her journey as a patient advocate.

Through social media, in 2013, Ms. Conway learned about the ACR’s Advocates for Arthritis, an annual event held in Washington, D.C. Since then, she has participated in the event three times. She has joined with rheumatologists and other patients to speak to members of the U.S. Senate and House of Representatives about the needs of rheumatology patients.

“Many politicians know the cost of drugs and the need for research, but they don’t truly understand the day-to-day needs of most rheumatology patients,” she says.

Being an advocate has changed her life. “It helped me stop having healthcare happen to me, and instead start having healthcare happen with me,” Ms. Conway says.

She explained to a healthcare aide in Rep. Patrick Meehan’s (R-Pen.) office that some drugs don’t work for certain people and that making patients go through the step therapy process is antiquated. Personally, Ms. Conway tried six different medications over a seven-year period before she could get a biologic drug that worked for her. The drugs that insurance companies deemed safer and more cost effective were actually ineffective for her.

“When I [started to] take a biologic drug on a higher tier level, I felt much better,” she says. “Politicians need to understand this. I want to be the voice that helps them understand.”

Page: 1 2 3 | Single Page
Share: 

Filed under:Conditions

Related Articles

    Methotrexate & Adverse Respiratory Events

    September 26, 2014

    A secondary review

    2017 ACR/ARHP Honors & Awards, Part 2

    January 19, 2018

    SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ARHP winners about their individual contributions. In addition, we profile the new class…

    Exploring Leflunomide’s Role in RA with Interstitial Lung Disease

    September 11, 2020

    Interstitial lung disease (ILD) is a hetero­geneous group of lung paren­chymal disorders that share several clinical, radiologic and histopathologic features, and are therefore grouped together.1 ILD can occur in association with most rheumatic connective tissue diseases (CTDs), but patients with systemic sclerosis, polymyositis, dermatomyositis and rheumatoid arthritis have the highest risk of developing ILD.2 A…

    The 2019 ARP Awards of Distinction & ACR Masters

    November 16, 2019

    ATLANTA—At the 2019 ACR/ARP Annual Meeting in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences